Cost-effectiveness of onabotulinumtoxinA versus topiramate in chronic migraine in the US: an economic analysis of the FORWARD randomized trial.

This study compared the cost-effectiveness of two migraine treatments: OnabotA and topiramate. Researchers focused on chronic migraine patients in the US. They used a complex model to evaluate costs and benefits over two years. The study analyzed data from the FORWARD trial, which provided information on headache days. It also considered how often patients stopped taking topiramate. Researchers calculated the costs associated with both treatments, including medication and medical visits. They looked at how much each treatment reduced headache days and improved quality of life. The results showed that OnabotA might be more effective in reducing headaches. It also offered better quality-adjusted life years compared to topiramate. The study helps inform decisions for healthcare providers and patients regarding migraine treatment options. Overall, it provides valuable insights into the economic aspects of chronic migraine management. Clinical relevance: This research indicates that OnabotA may provide better value than topiramate for chronic migraine treatment, helping clinicians choose more effective therapies for their patients.